InvestorsHub Logo
Followers 2
Posts 410
Boards Moderated 0
Alias Born 02/03/2017

Re: None

Tuesday, 07/24/2018 9:02:21 AM

Tuesday, July 24, 2018 9:02:21 AM

Post# of 330349
MundiPharma has the exclusive Australian and New Zealand distribution rights to the ActiPatch® Musculoskeletal Pain Therapy medical device.

What are the implications of having exclusive distribution rights?

Did they have to purchase the exclusive rights from BIEL?

Trying to put together what just this relationship alone means as well as the exclusive part.

What about adding the actipatch to the health care services such as NHS but for Australia and New Zealand?